Deglucohellebrin: A Potent Agent for Glioblastoma Treatment

(E-pub Ahead of Print)

Author(s): Evrysthenis Vartholomatos, George A. Alexiou*, Georgios S. Markopoulos, Diamanto Lazari, Olga Tsiftsoglou, Ieremias Chousidis, Ioannis Leonardos, Athanasios P. Kyritsis.

Journal Name: Anti-Cancer Agents in Medicinal Chemistry
(Formerly Current Medicinal Chemistry - Anti-Cancer Agents)

Become EABM
Become Reviewer


Background: Glioblastoma is the most common primary brain tumor in adults with dismal prognosis. To date several anticancer agents have been isolated from plants. Helleborus odorus subsp. Cyclophyllus is an endemic plant of the Balcan flora. Herewith, we investigated for the first time the anti-glioma effect of deglucohellebrin (DGH) extracted from roots of Helleborus.

Methods: We investigated the effect of DGH in U251MG, T98G and U87G glioblastoma cell lines. We selected the T98G cells because of their inherent temozolomide resistance.

Results: The IC50 value of reduced viability for DGH was 7x10-5M in U251MG cells, 5x10-5M for the T98G cells and 4x10-5M in U87G cells during 72-h treatment. DGH induced G2/M cell cycle arrest, caspace-8 activation and significant mitochondrial membrane depolarization suggesting activation of the intrinsic, mitochondrial dependent apoptotic pathway. DGH and temozolomide induced changes in CDs expression in U251MG and T98G cells. In zebrafish, DGH did not induce toxicity or behavioral alterations.

Conclusion: The present study is the first to determine the anti-glioma activity of DGH. DGH may be a potent agent for glioblastoma treatment and further studies are needed.

Keywords: Glioblastoma, Treatment, Deglucohellebrin, Zebrafish, Prognosis, G2/M cell cycle arrest

Rights & PermissionsPrintExport Cite as

Article Details

(E-pub Ahead of Print)
DOI: 10.2174/1871520619666191121110848
Price: $95